Clinical Trial Update: Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating camrelizumab combined with apatinib, paclitaxel-albumin, and S-1 for gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Apatinib Mesylate (apatinib)
• Camrelizumab (camrelizumab)
• S-1 (tegafur/gimeracil/oteracil)
• paclitaxel-albumin (paclitaxel-albumin)

Snippet

Sponsor: Beijing Friendship Hospital | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN